MaaT Pharma: Increase in Resources Allocated to the Liquidity Contract With the Brokerage Firm Kepler Cheuvreux
10 October 2023 - 3:00AM
Business Wire
Regulatory News:
MaaT Pharma (EURONEXT: MAAT – the “Company”), a
clinical-stage biotechnology company and a leader in the
development of Microbiome Ecosystem TherapiesTM (MET) dedicated to
enhancing survival for patients with cancer, announced an
increase in the resources allocated to the liquidity contract with
the brokerage firm Kepler Cheuvreux.
An additional contribution of 50,000 euros was made on October
6th, 2023, under the liquidity contract implemented since March 22,
2022. Therefore, the updated resources allocated to the liquidity
account are:
It is recalled that as of September 29th, 2023, the following
resources appeared on the liquidity account:
- 20,238 shares of MaaT Pharma
- € 12,244.51
The execution of the liquidity contract could be suspended under
the conditions set out in Article 5 of AMF Decision 2021-01 of 22
June 2021. As a reminder, the liquidity contract may be
terminated:
- at any time by MaaT Pharma without notice
- at any time by Kepler Cheuvreux, subject to thirty (30)
calendar days' notice
- without notice and without formality if the shares are
transferred to another stock market
The implementation of this liquidity agreement, pursuant to the
renewed authorization granted by the resolutions 20 & 21 of the
General Meeting held on June 19, 2023, has been carried out in
accordance with the legal framework in force, and more particularly
to the provisions of Regulation (EU) No. 596/2014 of the European
Parliament and of the Council of April 16, 2014 on market abuse
(MAR), Commission Delegated Regulation (EU) 2016/908 of February
26, 2016 supplementing Regulation (EU) No. 596/2014 of the European
Parliament and of the Council with regulatory technical standards
on the criteria, procedure and requirements for the establishment
of an admitted market practice and the requirements for
maintaining, discontinuing or modifying its conditions of
admission, Articles L. 225-209 et seq. of the French Commercial
Code and AMF decision no. 2021-01 of June 22, 2021, applicable as
of July 1, 2021.
About MaaT Pharma
MaaT Pharma, a clinical stage biotechnology company, has
established a complete approach to restoring patient-microbiome
symbiosis in oncology. Committed to treating cancer and
graft-versus-host disease (GvHD), a serious complication of
allogeneic stem cell transplantation, MaaT Pharma has launched, in
March 2022, an open-label, single arm Phase 3 clinical trial in
patients with acute GvHD, following the achievement of its proof of
concept in a Phase 2 trial. Its powerful discovery and analysis
platform, gutPrint®, enables the identification of novel disease
targets, evaluation of drug candidates, and identification of
biomarkers for microbiome-related conditions. The company’s
Microbiome Ecosystem Therapies are produced through a standardized
cGMP manufacturing and quality control process to safely deliver
the full diversity of the microbiome, in liquid and oral
formulations. MaaT Pharma benefits from the commitment of
world-leading scientists and established relationships with
regulators to support the integration of the use of microbiome
therapies in clinical practice. MaaT Pharma is listed on Euronext
Paris (ticker: MAAT).
View source
version on businesswire.com: https://www.businesswire.com/news/home/20231009394694/en/
MaaT Pharma – Investor Relations Guilhaume DEBROAS, Ph.D.
Head of Investor Relations +33 6 16 48 92 50 invest@maat-pharma.com
MaaT Pharma – Media Relations Pauline RICHAUD Senior PR
& Corporate Communications Manager +33 6 14 06 45 92
media@maat-pharma.com Trophic Communications – Corporate
Communications Charlotte SPITZ or Stephanie MAY +49 171 351
2733 maat@trophic.eu
Maat Pharma (EU:MAAT)
Historical Stock Chart
From Jun 2024 to Jul 2024
Maat Pharma (EU:MAAT)
Historical Stock Chart
From Jul 2023 to Jul 2024